SCHEMBL20536034

SCHEMBL20536034

Clc1cc2[nH]c(-c3ccncc3)nc2c(Br)c1Cl

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RHEB Q15382 5/20 0.76
▸ PKN1 Q16512 4/20 0.50
▸ PKN2 Q16513 4/20 0.50
▸ GAA P10253 2/20 0.46
▸ MGAM O43451 1/20 0.46
▸ SI P14410 1/20 0.46
▸ MGAM2 Q2M2H8 1/20 0.46
▸ KDM4E B2RXH2 3/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ HPGD P15428 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ MITF O75030 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ BLM P54132 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7742250 0.74 EGLN1 (0.47) RHEBGAAKDM4EALDH1A1HPGD
SCHEMBL7734320 0.74 EGLN1 (0.47) RHEBGAAKDM4EALDH1A1HPGD
SCHEMBL11225571 0.73 RHEB (1.00) RHEBPKN1PKN2GAAKDM4E
SCHEMBL16499582 0.72 MGAM (0.61) RHEBPKN1PKN2GAAMGAM
SCHEMBL23709817 0.71 RHEB (0.94) RHEBPKN1PKN2KDM4EALDH1A1
SCHEMBL23709831 0.70 RHEB (0.79) RHEB
SCHEMBL20536548 0.68 RHEB (0.62) RHEBPKN1PKN2KDM4EALDH1A1
SCHEMBL7164761 0.66 RHEB (0.69) RHEBPKN1PKN2GAAKDM4E
SCHEMBL7164766 0.66 KDM4E (0.73) RHEBPKN1PKN2GAAKDM4E
SCHEMBL28391018 0.66 MMP13 (0.69) RHEBPKN1PKN2GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 — — US disclosed
WO-2018191146-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS RHEB 1/4885PKN1 4109/4885PKN2 3958/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS RHEB 1/4885PKN1 1977/4885PKN2 1733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback